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This editorial refers to ‘Recurrence of ventricular arrhyth-
mias in ischaemic secondary prevention implantable
cardioverter deﬁbrillator recipients: long-term follow-up
of the Leiden out-of-hospital cardiac arrest study
(LOHCAT)’
†, by C.J.W. Borleffs et al.,o np a g e1 6 2 1
Once implantable cardioverter deﬁbrillators (ICDs) were proven
effective in treating ventricular tachycardias (VTs) and reducing
sudden death and total mortality,
1 arrhythmologists felt a kind of
relief for a while, a feeling that ‘the task has been completed’. That
is all an arrhythmologist can do for a VT patient at risk for sudden
death. Cardiac resynchronization therapy (CRT) put everybody
back in the saddle again, and now large studies have shown that
CRT alone or in combination with an ICD also reduces mortality in
patients with advanced heart failure and a wide QRS.
2 It seemed
that arrhythmologists could take a break again. However, the stabiliz-
ationofthe ﬁeldwasonceagainanillusion,asnewstudiessuchasthe
report by Borleffs et al.
3 send us in new directions. The question is:
now that the deﬁbrillator is in place, what else can we do for our
patients to improve their quality of life and survival?
Borleff et al. analysed which baseline variables in patients receiv-
ing a deﬁbrillator for secondary prevention are predictive of recur-
rent life-threatening ventricular arrhythmias and mortality. The
main independent predictors were atrial ﬁbrillation (AF), wide
QRS, ejection fraction, and VT as a presenting arrhythmia. Theor-
etically, these four predictors can be modiﬁed at the moment of
ICD implantation, and therefore there is plenty of scope for
research to demonstrate that taking the necessary steps to do
so will further beneﬁt patients in the long run.
The obvious and already proven beneﬁt is to implant a CRT in
Class III–IV patients with a wide QRS.
2 However, in the near
future, new data will be available from studies of patients in
Class II. The INCIDENCE and MADIT III
4 studies are analysing sec-
ondary and primary prevention patients, respectively, and may
clarify whether better results are obtained from implanting a
CRT, rather than conventional ICD devices, in Class II patients
with a wide QRS and severe left ventricular dysfunction.
The results of the REVERSE trial demonstrated that implanting a
CRT at an early stage of the disease (Class I and II) induces
reverse remodelling, without deﬁnitively establishing any functional
beneﬁt.
5 Although several small studies have found potential for
CRT in patients with a narrow QRS, until now this has not been
proven in a large randomized study. The potential beneﬁt of
CRT in patients with a narrow QRS is being explored by the
ECHO-CRT trial,
6 which is recruiting patients with severe systolic
dysfunction and dyssynchrony, proven by echocardiographic cri-
teria. The aim is to establish whether patients with a narrow
QRS could also beneﬁt from CRT therapy.
AF is mentioned in Borleffs et al. as the most powerful predictor
of life-threatening arrhythmias and death. Despite its association
with increased mortality, for many years AF was thought
merely to represent a marker of more severe disease, rather than
being a cause itself of increased mortality. More recently, epidemio-
logical studies
7 have ﬁrmly established the link between increased
mortality and AF, after adjusting for relevant covariates such as
age, heart disease, etc. Therefore, there is an increasing awareness
of the independent negative prognostic value of AF in several clinical
situations. For example, AF is independently associated with
increased mortality in primary prevention ICD trials
8 and in patients
with heart failure, even when treated with CRT.
9
What are the possible mechanisms that link AF and mortality?
On one hand is the worsening of heart failure. Fast, irregular ven-
tricular rhythm and loss of atrial contraction certainly will decrease
cardiac output and precipitate heart failure. Furthermore, chronic
fast rhythm induces the so-called ‘tachycardiomyopathy’ with ven-
tricular dilatation and remodelling, mimicking dilated cardiomyopa-
thy. The study by Borleffs et al.
3 suggests another interesting
hypothesis. In that study, AF was a predictor of appropriate
shocks, suggesting that AF plays an important role in inducing ven-
tricular arrhythmias. In fact, several case reports and studies have
shown that a fast irregular ventricular rhythm induces ventricular
arrhythmias. Therefore, whether through worsening the ventricu-
lar remodelling to cause heart failure or by provoking ventricular
tachycardia, AF may increase mortality.
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sing AF and improving ventricular function in selected patients,
10
and,therefore,intheory,mayofferanopportunityforimprovement
insuchpatients.BoththeAMICAtrial
11andthatdescribedinNatale
et al.
12 are attempting to demonstrate a beneﬁt of AF ablation in
patients who receive an ICD for primary and secondary prevention
or for depressed left ventricular ejection fraction.
Finally, Borleffs et al.
3 identify VT at baseline as an independent
predictor. It is well known that patients with VT have more
severe LV dysfunction than patients presenting with ventricular
ﬁbrillation. On the other hand, patients with VT tend to suffer
more recurrences than do those presenting with ventricular ﬁbrilla-
tion(VF).Therefore,thenegativeeffectofVTonprognosiscouldbe
related to a worse baseline proﬁle, but also to a higher number of
shocks. In fact, several studies have proven that patients suffering
shocks have a worse prognosis, although no casual relationship
has been clearly established so far.
13 Repeated VT episodes or
shock may have an additive negative effect. On the other hand,
ICD shocks (whether appropriate or not) have a negative impact
on quality of life. Therefore, any step towards decreasing the
number of arrhythmic episodes (ventricular or supraventricular)
may in theory have a positive impact on the course of the disease.
The recentSMASH VT study
14 has shownthatprophylacticVT sub-
strate ablation decreases the number of ICD therapies during
follow-up. As a result, perhaps in the near future prophylactic abla-
tion therapy at the time of implantation will be promoted. Other
trials are in progress, attempting to demonstrate this hypothesis.
15
In summary, there are several actions, such as CRT, AF ablation,
or VT ablation, that may improve the quality of life and prognosis in
patients receiving an ICD for secondary prevention. The results of
several ongoing trials may shed more light on the road ahead.
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Middle aortic syndrome, severe hypertension, and endovascular repair
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A 55-year-old woman presented to the emergency room with dyspnoea, epigastric
pain,anddizziness.Shewasseverelyhypertensive.Physicalexaminationrevealedasys-
tolicmurmurintheleftsternaledge(II/VI),bilateralbasalrales,andabsenceofpulseson
both lower limbs. The chest radiographysupported the diagnosis ofacute pulmonary
oedema. The 12-lead electrocardiogram showed sinus tachycardia with non-speciﬁc
changesofrepolarization.Echocardiographyshowedsevereconcentricleftventricular
hypertrophy and low ejection fraction. Thoraco-abdominal CT was performed
showing a critical and severely calciﬁed aortic stenosis in the junction between the
thoracicandtheabdominalsegmentsoftheaorta(PanelsAandB). Aortography con-
ﬁrmed the presence of severe stenosis of descending aorta with a gradient of
160 mmHg. The patient underwent urgent percutaneous stent implantation with
an acceptable luminal gain and a residual gradient of 30 mmHg (Panels C, D, and
E). The patient’s haemodynamic condition improved during the next few hours fol-
lowing the endovascular procedure, and she was discharged asymptomatic 1 week
later. Three months after hospital discharge, her blood pressure remains normal.
Middleaorticsyndromeisadiffusenarrowingofthedistalthoracicandabdominal
aortathat commonlyinvolvesthe visceral and renalarteries. This conditiontypically
presentsasseverehypertensioninyoung patientswhohaveweakorabsentfemoral
pulses and an abdominalor lower back bruit. Theaetiologyof themiddle aortic syn-
drome is controversial. The diagnosis of this rare syndrome is made by computed
tomography, magnetic resonance imaging, or angiography. The natural history of
this rare syndrome is unknown. Most authors agree that these patients should
undergo revascularization whenever feasible. Aorto-aortic bypass, patch aortoplasty, and percutaneous techniques are the most
frequent approaches used for the treatment of patients with middle aortic syndrome.
Panel A. Non-contrast computer tomography shows a severe calciﬁed stenosis in the transition from the thoracic aorta to the
abdominal aorta.
Panel B. The same lesion at a coronal view.
Panel C. The sequence of percutaneous intervention (pre- and post-intervention).
Panels D and E. Multidetector computer tomography showing the implanted stent at axial and sagittal views.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.
Editorial 1553